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Abstract
We have identified a series of tetrahydrocarbazoles as novel P-type ATPase inhibitors.
Using a set of rationally designed analogues, we have analyzed their structure-activity rela-
tionship using functional assays, crystallographic data and computational modeling. We
found that tetrahydrocarbazoles inhibit adenosine triphosphate (ATP) hydrolysis of the fun-
gal H+-ATPase, depolarize the fungal plasma membrane and exhibit broad-spectrum anti-
fungal activity. Comparative inhibition studies indicate that many tetrahydrocarbazoles also
inhibit the mammalian Ca2+-ATPase (SERCA) and Na+,K+-ATPase with an even higher
potency than Pma1. We have located the binding site for this compound class by crystallo-
graphic structure determination of a SERCA-tetrahydrocarbazole complex to 3.0 Å resolu-
tion, finding that the compound binds to a region above the ion inlet channel of the ATPase.
A homology model of the Candida albicans H+-ATPase based on this crystal structure, indi-
cates that the compounds could bind to the same pocket and identifies pocket extensions
that could be exploited for selectivity enhancement. The results of this study will aid further
optimization towards selective H+-ATPase inhibitors as a new class of antifungal agents.
Introduction
Invasive fungal infections (IFIs) are a significant threat to human health, especially among
immunocompromised, elderly or hospitalized individuals. Despite the availability of a number
of treatments, IFIs result in approximately 1.5 million deaths worldwide annually [1]. IFIs are
generally associated with high mortality rates, often above 50%, and can approach 90% for
some infections. The major IFIs are caused by Candida, Aspergillus and Cryptococcus species
[1]. Many of the currently available therapies exhibit poor toxicology profiles (amphotericin
B) [2], extensive drug-drug interactions (azoles), and are beginning to suffer from acquired
resistance among pathogenic species (azoles and echinocandins) [3,4]. In addition, many
antifungals have a limited spectrum of activity and appropriate treatment is often delayed by
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The fungal H+-ATPase Pma1 belongs to a family of membrane-embedded ATPases that
pump ions across cellular membranes, a process energized through transient phosphoryla-
tion by ATP. Pma1 pumps H+ out of the cell, generating a large membrane potential, which
drives secondary transporters to import ions and metabolites, such as glucose and amino
acids [7]. Pma1 has been shown to be an essential membrane protein through pma1 gene dis-
ruption, RNA interference studies [8] and loss-of-function mutations of Pma1 in yeast [9].
Pma1 is present in all fungi with a high degree of sequence similarity among diverse fungal
pma1 genes (50–96%) but is not present in mammalian cells. A selective Pma1 inhibitor is
therefore very likely to have broad-spectrum antifungal activity and no target associated tox-
icity. Several clinically important therapeutics target other members of the P-type ATPase
family. For example, cardiac glycosides target the Na+,K+-ATPase and proton pump inhibi-
tors (PPIs), such as omeprazole, target the gastric H+,K+-ATPase [10]. The establishment
of the P-Type ATPases as a druggable class of targets suggests that it should be possible to
develop Pma1 inhibitors as potent antifungal agents. Notably, Pma1 inhibitors could act
from the extracellular side, similar to PPIs, and circumvent the challenges associated with
crossing the fungal plasma membrane.
Here we report a compound library screening campaign that identified a series of Pma1
inhibitors that exhibit broad-spectrum antifungal activity. Computer modeling, supported by
structural biology indicates that the compounds bind to a groove at the intracellular mem-
brane interface, similar to other P-type ATPase inhibitors that block the ion entry channel.
Results
Tetrahydrocarbozole compounds inhibit ATP hydrolysis by P-type
ATPases
20,240 compounds were screened for inhibition of Pma1 ATP hydrolysis at a single concentra-
tion (20 μM) to identify initial hits with potency in the low micromolar range. One hundred
compounds exhibited >30% Pma1 inhibition, and were selected for Pma1 IC50 determination,
and then evaluated for antifungal activity against Saccharomyces cerevisiae (baker’s yeast) and
Candida albicans (ATCC 90028). Two-thirds of the Pma1 inhibitors also inhibited fungal
growth of S. cerevisiae and C. albicans at concentrations below< 100 μM, while the remaining
compounds did not inhibit fungal growth. A series of tetrahydrocarbozoles stood out as inhibi-
tors of both Pma1 activity and fungal growth in the low micromolar range (<20 μM). These
compounds were repurchased and confirmed as Pma1 inhibitors (compound 1–3, Fig 1,
Table 1).
Nine tetrahydrocarbazole compounds (4–12, Fig 1) were synthesized (see S1 File for details)
and the racemic compounds were tested for activity against Pma1 and the related mammalian
Ca2+-ATPase (SERCA, rabbit) and Na+,K+-ATPase (pig) (Table 2). Compounds 4 and 5 were
weak inhibitors of Pma1, and compounds 11 and 12 exhibited no activity against Pma1. Com-
pounds, 6–10 inhibited Pma1 in the low micromolar range (IC50 values of 2–9 μM). Com-
pounds 6, 7, and 8 were more potent in inhibiting SERCA and the Na+,K+-ATPase than
Pma1, and compound 12 was weakly selective for Na+,K+-ATPase only (IC50 = 11.8 μM).
Compounds 9 and 10 were potent Pma1 inhibitors (IC50 = 5–7 μM) and exhibited antifungal
activity in the same concentration range against Saccharomyces cerevisiae, Candida albicans
and Candida krusei (Table 3, and see below).
Tetrahydrocarbazoles inhibit the fungal H+-ATPase
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Fig 1. Chemical structure of the tetrahydrocarbazole scaffold (top), three initial hits from the library screening
(1–3) and nine rationally designed tetrahydrocarbazole analogues used in this study (4–12). The chiral center is
indicated by an asterisk.
https://doi.org/10.1371/journal.pone.0188620.g001
Table 1. ATP hydrolysis and growth inhibition by library hit compounds. MIC is defined as 50% growth inhibition, n = 3.
ATP hydrolysis IC50 [μM] Growth inhibition MIC [μM]
ID Saccharomyces cerevisiaePma1 Saccharomyces cerevisiae Candida albicans
1 18.2 ±4.7 10 20
2 12.9 ±3.2 12 10
3 14.8 ±3.5 12 5
https://doi.org/10.1371/journal.pone.0188620.t001
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Tetrahydrocarbazoles exhibit broad spectrum fungistatic activity
Compounds 6–10 exhibited the broadest spectrum of antifungal activity, inhibiting the growth
of the yeasts Saccharomyces cerevisiae, Candida albicans, Candida krusei and Candida glabrata.
The compounds were less potent than voriconazole (VRC) and amphotericin B (AMB) against
all fungal isolates tested, but more potent than fluconazole (FLC) on S. cerevisiae, C. krusei and
C. glabrata (Table 3). They were also more potent than other, structurally different compound
series identified in this and previous library screens, the carbazoles [11] and the pyrido-thieno-
pyrimidines [12]. The less potent Pma1 inhibitors 4 and 5 displayed weak antifungal activity.
Compounds 11 and 12, despite their very close structural similarity to 10, exhibited neither
substantial Pma1 inhibition nor antifungal activity (IC50 and MIC >20 μM). Finally, one of
the synthesized tetrahydrocarbazole compounds, 9, exhibited antifungal activity against the C.
glabrata strain Cg003, which overexpresses the efflux pumps Cdr1p and Cdr2p associated with
multidrug resistance [13].
Table 2. IC50 values of compounds 4–12 against ATP hydrolysis activity of fungal and mammalian P-type ATPases. n = 3.
ID ATP hydrolysis IC50 [μM]
Saccharomyces cerevisiaePma1 Candida albicans Pma1 Mammalian SERCA Mammalian Na+,K+-ATPase
4 75.0 ±3.2 46.0 ±14.5 1.55 ±0.06 37.2 ±13.6
5 85.9 ±10.3 129.7 ±32.2 61.7 ±18.8 131.9 ±35.2
6 2.79 ±0.36 3.89 ±1.71 0.09 ±0.03 0.72 ±0.30
7 2.43 ±0.39 2.47 ±0.26 0.11 ±0.06 0.38 ±0.12
8 3.57 ±1.81 3.77 ±1.04 0.26 ±0.06 1.07 ±0.38
9 4.73 ±2.23 5.56 ±1.55 3.27 ±1.89 9.76 ±4.47
10 6.69 ±2.06 9.70 ±2.15 5.54 ±3.16 5.50 ±2.74
11a >20 >20 >20 >20
12a >20 >20 >20 11.8 ±6.8
aThe compounds were tested in a concentration up to 166 μM, but compound precipitation was observed at concentrations above 20 μM.
https://doi.org/10.1371/journal.pone.0188620.t002
Table 3. Fungal growth inhibition by compounds 4–12. MIC is defined as 50% growth inhibition, n = 3–6. FLC: fluconazole; VRC: voriconazole; AMB: amphotericin B.
Growth inhibition MIC [μM] EC50 [μM]
ID Saccharomyces cerevisiae ATCC
9763
Candida albicans
SC5314
Candida kruseiATCC
6258
Candida glabrata ATCC
90030
Candida glabrata
Cg003
HepG2 (72
h)
4 7.5 ±0.0 100 ±43 66 ±16 23.7 ±0.0 75 ±0.0 3.50 ±1.87
5 11.6 ±8.1 150 ±0.0 150 ±0.0 46.5 ±27 >75 4.70 ±3.40
6 5.0 ±2.9 7.5 ±0.0 7.5 ±0.0 12.1 ±7.9 >75 16.69 ±3.54
7 1.5 ± 0.0 15 ±0.0 4.7 ±0.0 15 ±0.0 >75 14.87 ±0.26
8 6.2 ±2.6 7.5 ±0.0 12.9 ±9.4 5.3 ±2.7 >75 13.60 ±1.33
9 7.5 ±0.0 7.5 ±0.0 7.5 ±4.8 7.5 ±0.0 23.7 ±0.0 12.45 ±3.68
10 7.5 ±0.0 6.8 ±4.6 6.8 ±4.6 21.0 ±6.6 >75 18.64 ±1.12
11a >20 >20 >20 >20 >20 >20
12a >20 >20 >20 >20 >20 >20
FLC 20.68 ±8.68 0.75 ±0.48 67.17 ±26.98 26.12 ±0.0 >208 >50
VRC 0.27 ±0.19 0.03 ±0.02 1.02 ±0.70 0.61 ±0.28 6.11 ±2.64 >50
AMB 0.02 ±0.01 0.10 ±0.04 0.44 ±0.34 0.10±0.04 0.18±0.08 0.69 ±0.01
aThe compounds were tested in concentrations up to 75 μM in the fungal growth assay and up to 50 μM against HepG2 cells, but compound precipitation was observed
at concentrations above 20 μM.
https://doi.org/10.1371/journal.pone.0188620.t003
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Compounds were evaluated for mammalian cytotoxicity in a standard human hepatocyte
cell proliferation assay (HepG2). All nine tested tetrahydrocarbazoles inhibited HepG2 prolifer-
ation (EC50: 3–20 μM) more strongly than VRC, but less than AMB (EC50:< 1 μM) (Table 3).
Compounds 4 and 5 were more potent at inhibiting HepG2 proliferation than fungal growth.
Although compounds 6, 8, 9 and 10 inhibited fungal growth more strongly than HepG2 prolif-
eration, the issue of mammalian cytotoxicity will need to be addressed during further develop-
ment of the compounds. However, the broad range of EC50 values obtained in the proliferation
assay, from very cytotoxic to moderate or no toxicity, indicate that the cytotoxicity profile of
these compounds can be optimized to increase the selectivity towards fungal cells.
Compounds 6 and 8 were evaluated in time-kill experiments against Candida albicans.
Here, exposure to 6 or 8 (20 μM) resulted in a rapid reduction in colony-forming units (CFU),
compared to dimethylsulfoxide (DMSO) treated controls at T = 0 h (Fig 2A). After 3 h expo-
sure,>99% reduction in CFU was observed for cells treated with 6 or 8, but after 6 h exposure,
these cultures yielded CFU counts similar to DMSO-controls (Fig 2A). The low CFU counts at
T = 3 h were similar to observations for AMB, which is fungicidal after 3 h exposure in C. albi-
cans, and distinct from VRC which exhibits fungistatic activity after both 3 and 24 h of incuba-
tion. Thus, the fungal growth data observed for Candida cells exposed to 6 and 8 suggests that
the tetrahydrocarbazoles both delay growth and displayed fungistatic activity after 24 h of
incubation.
Compounds 6 and 8 elicit a long post-antifungal effect (PAFE) after brief exposure in C.
albicans cells (Fig 2B). PAFE is assessed by the ability of fungal cells to grow and divide follow-
ing compound exposure, and is determined by following the number of CFU/mL in com-
pound-free culture. Fig 2B shows the PAFE after 1 h exposure of C. albicans to AMB, VRC or
compounds 6 or 8. Exposure to AMB (0.54 μM) significantly delayed the growth of C. albicans
cells, with CFU counts only beginning to rise 7 h after compound removal (PAFE = 7 h). Cells
exposed to VRC (2.8 μM) exhibited no significant delay in growth following the same exposure
period as compared to untreated cells. Exposure to compounds 6 or 8 (20 μM) led to a 5 h
delay in growth as compared to DMSO-treated controls (PAFE = 5 h), a similar effect to
that observed with AMB. Once cells that had been exposed to tetrahydrocarbazoles resumed
growth they divided rapidly, as evidenced by an exponential increase in CFU counts between 3
and 7 h following compound removal (Fig 2B).
Tetrahydrocarbazoles induce membrane depolarization without affecting
membrane integrity
We assessed the membrane potential and integrity of S. cervevisiae cells exposed to 10 μM tet-
rahydrocarbazoles using the fluorescent probes bis-(1,3-dibutylbarbituric acid)trimethine oxo-
nol (DiBAC4(3)) and propidium iodide (PI). DiBAC4(3) can enter depolarized cells where it
binds to intracellular proteins, leading to an enhancement of the fluorescent signal [14]. PI
exhibits increased fluorescence upon binding to DNA, and is commonly used as a marker for
loss of membrane integrity and the presence of dead cells [15]. No significant differences in
the fluorescence signal for DiBAC4(3) were observed for S. cerevisiae cells treated with 4 or 5
as compared to DMSO after 30 minutes exposure (Fig 3). Exposure of S. cerevisiae to 10 (S. cer-
evisiae Pma1 IC50 = 7 μM) led to a slight increase in the DiBAC4(3) fluorescence intensity,
while exposure to the slightly more potent Pma1 inhibitors 6–9 (S. cerevisiae Pma1 IC50 =
2–5 μM) led to a significant increase in the fluorescence signal indicative of membrane depo-
larization induced by these compounds (Fig 3). None of the compounds induced an increase
in PI fluorescence, indicating that membrane integrity was not affected. An overview of the
results from the membrane potential assays is presented in Fig 3 and Figure A in S1 File.
Tetrahydrocarbazoles inhibit the fungal H+-ATPase
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The observed effects indicate a concurrence of antifungal activity with a loss in membrane
potential, which would be consistent with a mechanism involving Pma1 inhibition rather than
unspecific membrane damage.
Crystal structure of an inhibitory P-type ATPase • tetrahydrocarbazole
complex
To complement the functional data of the tetrahydrocarbazole compounds with structural
information, we collected X-ray diffraction data of an inhibitory complex of compound 7
bound to SERCA (rabbit isoform 1a). This complex was formed in a Ca2+-free so-called E2
state and used an ATP analogue, TNPATP, to stabilize the flexible nucleotide-binding region
Fig 2. Antifungal activity of tetrahydrocarbazoles against C. albicans. A) Time-kill analysis and B) Post-antifungal
effect of tetrahydrocarbazoles:● = DMSO-treated control cells,  = cells treated with AMB (0.54 μM),  = cells treated
with VRC (2.8 μM), □ = cells treated with 6 (20 μM) and ^ = cells treated with 8 (20 μM). Values in A) and B) are the
mean (±SEM) for three independent experiments. Samples withdrawn at the indicated times in A) and B) were
evaluated for CFU.
https://doi.org/10.1371/journal.pone.0188620.g002
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of SERCA, which has been well characterized both functionally and structurally [16–26]. The
3.0 Å crystal structure of the inhibitory complex shows compound 7 bound at the cytosolic
membrane interface, in a groove between transmembrane helices M1, M2, M3 and M4 (Fig
4A and 4B).
Despite the modest resolution of 3.0 Å, difference electron density maps clearly allow the
placement of bound TNPATP at the ATPase active site (Figure B in S1 File), two lipid mole-
cules at the luminal membrane interface (modeled as DOPC, Figure B in S1 File), and of com-
pound 7 which is cradled deep inside the cavity marking the cytoplasmic end of the Ca2+ inlet
channel of SERCA (Figs 4A, 5A and 5B). Its position superimposes with previously co-crystal-
lized SERCA inhibitors 2,5-di-t-butyl-1,4-benzohydroquinone (BHQ) [22] and cyclopiazonic
acid (CPA) [25] (Fig 4B and Figure C in S1 File).
The tetrahydrocarbazole core of 7 is clearly visible in an mFo-DFc electron density omit
map contoured at 3 σ, but the bromo-phenyl moiety is poorly defined, probably due to an
inherent flexibility in the linker connecting it to the tetrahydrocarbazole core. However, an
anomalous difference map visualizing the isolated signal from the heavy bromine atom in 7
reveals two distinct peaks (5.7 and 7.3 σ) in close vicinity to the tetrahydrocarbazole core (Fig
5A). A model with two alternative conformations of the bromo-phenyl moiety, with an occu-
pancy of 0.5 each, allowed a straightforward placement of the bromine atoms into both anom-
alous peaks. One of the two orientations allows for a staggered stacking interaction between
the bromo-phenyl group and the tetrahydrocarbazole core. The tetrahydrocarbazole core
(modeled with an occupancy of 1) is held in place by three polar contacts to SERCA residues
D59 on M1, N101 on M2 and D254 on M3, as well as several hydrophobic interactions involv-
ing V62, L65, L98, L253, I307, P312, I315, and the Cβ and Cγ -atoms in the side chain of E309
(Fig 5A and 5B). The pocket extends further towards the inner core of the SERCA protein,
bounded by F256 and P308, and also upwards towards the P-domain (Fig 5C, Figure D in S1
File).
Fig 3. Membrane depolarization effect of tetrahydrocarbazoles. Percentage of fungal cell population measured as PI and
DiBAC4(3) positive (+) and negative (-) after 30 minutes exposure to tetrahydrocarbazoles (10 μM final concentration).
Error bars indicate SEM. Compounds 6–10 lead to membrane depolarization (increase in DiBAC4(3) signal) with minimal
effect on membrane integrity (no increase in the PI signal). n = 3 for lysis buffer and n = 6 for DMSO control and the
compounds.
https://doi.org/10.1371/journal.pone.0188620.g003
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Fig 4. Crystal structure of the SERCA•7•TNPATP complex. A) Cartoon representation of the SERCA•7•TNPATP
complex. Domains and ligand-binding sites are indicated. Compound 7 (carbon in yellow, oxygen in red, bromine in
dark red, fluorine in pale cyan, nitrogen in blue) and TNPATP (carbon in marine, oxygen in red, phosphorous in
orange, nitrogen in blue) are shown in stick representation. B) Sliced surface representation revealing the position of
the ligand-binding pocket at the cytosolic membrane interface (TNPATP omitted for clarity, colors as in A).
https://doi.org/10.1371/journal.pone.0188620.g004
Fig 5. The binding pocket of compound 7. A) Compound 7 with polar and hydrophobic interactions and mFo-DFc difference electron density
map before the ligand was modeled (green, contoured at 3 σ) and anomalous difference map (orange, contoured at 4.5 σ, calculated using phases of
the final refined model and anomalous difference data from 56–6 Å resolution). B) Slightly rotated view of the ligand binding site, revealing the
position of the functionally important residue E309 in SERCA. C) Close-up view of the mostly uncharged surface of the ligand-binding site and its
extension towards the P-domain (asterisk). Carbon atoms are colored blue in SERCA and yellow in 7, oxygen red, nitrogen blue, bromine dark red,
and fluorine in pale cyan.
https://doi.org/10.1371/journal.pone.0188620.g005
Tetrahydrocarbazoles inhibit the fungal H+-ATPase
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Interestingly, the SERCA•7•TNPATP complex protein has crystallized in a previously
unreported crystal form, reflecting a novel overall conformation of the ATPase. Structural
alignment reveals the most similar known SERCA structures are–as expected–also in the
Ca2+-free E2 state, stabilized by the inhibitor thapsigargin (Tg) and TNPAMP, TNPADP and
TNPATP as nucleotide analogs (PDB ID 3AR5, 3AR6, and 3AR7, all-atom RMSD = 1.90 Å,
1.94 Å and 1.99 Å, respectively). Whereas the transmembrane regions superpose almost
identically (all-atom RMSD with 3AR7 = 0.736 Å), the three cytosolic domains (N-, P-, and
A-domains) in the SERCA•7•TNPATP structure have undergone a considerable positional
shift relative to the transmembrane helices (Figure E in S1 File). The three cytosolic domains
adopt positions roughly halfway in-between the Ca2+-free E2 and the Ca2+-bound E1 state.
In particular, the A-domain has undergone a significant movement and tilt (Figure E in S1
File), with the deviation starting at the cytosolic ends of M1 and M2, in the vicinity of the
binding site of compound 7 (Figure E in S1 File). It is therefore tempting to speculate that
compound 7 induces this new conformation, especially since neither Tg- nor TNPATP-
bound SERCA structures display any such substantial conformational changes as compared
to their ligand-free counterparts.
Pma1 homology model and docking of tetrahydrocarbazole compounds
The overall topological organization of all structurally characterized P-type ATPase family
members, such as SERCA, the Na+,K+-ATPase, the plant H+-ATPase, the CopA Cu2+-ATPase
and the Zn2+-ATPase [16–18,20,24,27–32], is very similar and it is therefore unlikely that the
Pma1 structure deviates significantly from its other family members. We generated homology
models of C. albicans Pma1 and pig Na+,K+-ATPase based on the SERCA•7•TNPATP com-
plex structure, to assess the potential for protein-ligand interactions in the respective binding
pockets. In the Pma1 model, the binding pocket is considerably larger than in SERCA, extend-
ing deeper into the core of the protein towards transmembrane helix M5, and forming a con-
tinuous channel towards the groove between M3, M5, and M7, which is a known binding site
of the inhibitor Tg in SERCA (Figure D in S1 File).
In an initial control, we attempted to dock both R- and S-isomers of compound 7 back into
the SERCA•7•TNPATP crystal structure with an empty compound binding site. The docking
pose with the second highest affinity score given by the Vina program (-9.2 kcal/mol) for the
S-isomer placed the compound almost identical to that modeled in the crystal structure (Fig
6A), whereas the R-isomer did not dock in a similar pose. The highest scoring solution for the
S-isomer placed the ligand into the thapsigargin binding groove between M3, M5 and M7, a
relatively wide and deep hydrophobic cleft apparently prone to false-positive sampling as we
found this site sampled by several of the alternative docking poses throughout. When docked
into the Pma1 homology model, however, the highest scoring docking poses of both enantio-
mers of compound 7 (-9.1 and -9.7 kcal/mol for the R- and S-isomer, respectively) adopt a
very similar docking pose to the binding mode observed in the SERCA crystal structure, with
key polar interactions to Q101, N267, and N130 (Fig 6B). The highest scoring poses for the
other compounds all occupy the same pocket, with relatively similar affinity scores between
-8.3 and -9.8 kcal/mol. Generally, compounds with a substituent not larger than a phenyl moi-
ety in position R1 (4–8) favor a docking pose in which the tetrahydrocarbazole core occupies a
similar position to that observed in the SERCA•7•TNPATP crystal structure. In the enzyme
and functional assays the compounds have only been tested as racemic mixtures, but the dock-
ing poses of 4–8 are very similar for the S and R-isomers. The R1 phenyl groups sample the
space between the two conformations observed in the SERCA•7•TNPATP complex (Fig 6C).
Compounds 9–12, with their larger biphenyl moieties in the R1 position, display a larger
Tetrahydrocarbazoles inhibit the fungal H+-ATPase
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variety of docking poses. Hence, the S-isomers of compounds 9–12 dock with slightly shifted
and/or tilted tetrahydrocarbazole cores relative to the configuration of 7, and with the biphenyl
moieties pointing roughly in the same directions as either one of the two conformations
observed in 7 (Fig 6D and 6E). With the exception of compound 12, where both R and S-iso-
mer dock with their tetrahydrocarbazole core in similar positions, the R-isomers of com-
pounds 9–11 adopt completely displaced positions within the binding site (Fig 6F).
From our structural and docking data, the poor binding affinity of compounds 11 and 12
for both Pma1 and SERCA can be rationalized by steric clashes in the binding sites. Com-
pound 11 posesses a methyl group at position R2 for which there is no space in the tetrahydro-
carbazole-binding pocket, resulting in a steric clash with D59 in SERCA, and Q101 in the
Pma1 model, and the methyl group on the nitrogen in R1 of compound 12 causes a steric clash
Fig 6. Docking poses of compounds 4–12. Oxygen, nitrogen, bromine, chlorine and fluorine atoms in red, blue, dark
red, green, and light blue, respectively. A) Docking (green) and experimental (yellow) binding mode of 7 to SERCA.
SERCA is shown as cartoon with carbon in blue, and amino acids D59, D254 and N101 are shown as sticks.
Compound 7 is shown as sticks with carbon in yellow. B-F) Docking of 4–12 into the C. albicans Pma1 homology
model. The Pma1 model is shown as cartoon with carbon in gray, and amino acids Q101, N130 and N267 are shown as
sticks. B) Docking of 7 (S)(green) and 7 (R) (orange) C) Docking of 4 (magenta), 5 (yellow), 6 (blue), 7 (green), 8
(pink) (all S). D) Docking of 9 (S) (magenta), and 10 (S) (yellow). E) Docking of 11 (S)(yellow), 12 (S) (blue), and 12
(R) (orange). F) Docking of 9 (brown), 10 (cyan), and 11 (yellow)(all R).
https://doi.org/10.1371/journal.pone.0188620.g006
Tetrahydrocarbazoles inhibit the fungal H+-ATPase
PLOS ONE | https://doi.org/10.1371/journal.pone.0188620 January 2, 2018 10 / 21
with D254 (N267 in Pma1): Both compounds display tilted docking poses and less favorable
interactions with the protein (Fig 6E).
None of the compounds adopted a docking pose in the Na+,K+-ATPase homology model
that was similar to the observed position of 7 in SERCA (Figure F in S1 File). This is due to the
conserved side chain of F100 (Na+,K+-ATPase pig numbering), which is located at the ‘kink’ of
M1 and points into the region where the tetrahydrocarbazole core would be expected to bind.
This F100 occupies a roughly equivalent position in all known Na+,K+-ATPase crystal struc-
tures and has previously been pinpointed as the cause for the inactivity of CPA against Na+,
K+-ATPase [25], making the observed inhibitory effect of the tetrahydrocarbazole compounds
dependent on an induced fit mechanism or a different binding site.
Discussion
Our screening approach has yielded a series of tetrahydrocarbazole Pma1 inhibitors with
promising antifungal activity. One third of the initial hit compounds exhibited no activity
against fungal growth despite being potent inhibitors of ATPase activity in vitro, probably
due a lack of ability to pass through the fungal cell wall. The physicochemical properties of the
fungal cell wall might block passage, compounds might be adsorbed or degraded by cell wall
located enzymes. The functional and structural data reveal that the Pma1-inhibitory and anti-
fungal activities of the tetrahydrocarbazoles are strongly dependent on the properties of the R1
linker that connects the core with the distal aromats. The most potent Pma1 inhibitors in this
study possess an NH-CH2-C sequence at R1 and only a hydrogen at R2.; compounds 6–10.
These compounds inhibit the ATP hydrolysis activity of Pma1, display antifungal activity and
depolarize the membrane potential of S. cerevisiae cells. Importantly, the PI signal remained
unchanged after 30 minutes of tetrahydrocarbazole exposure, indicating that membrane depo-
larization was a result of Pma1 inhibition rather than disruption of membrane integrity.
Based on the results from time-kill and PAFE studies and the membrane depolarization
and integrity experiments, we propose that 6 and 8 are rapidly taken up into fungal cells lead-
ing to inhibition of fungal growth. None of the compounds (6–10) significantly inhibited
the growth of C. glabrata (Cg003), a fungal strain with up-regulated efflux pump activity
(Table 3). This suggests that the compounds might be subject to efflux, although more studies
are required to confirm this.
The increased inhibition of Pma1 by 6–10 (compared to 4 and 5) could be due to the
increased number of hydrophobic interactions between the binding pocket and the hydropho-
bic R1 carbon chain. Even large biphenyl R1 substituents, such as in 9 and 10, are well toler-
ated, and these compounds are less potent inhibitors of SERCA and the Na+,K+-ATPase, as
compared to 6–8. Our Pma1 homology model indicates that the larger binding pocket in
Pma1, is better placed to accommodate large R1 substituents compared to SERCA (Figure D in
S1 File). A larger pocket in Pma1 is also consistent with the more permissive docking of both
enantiomers of 7, as compared to SERCA. Compounds 11 and 12 are very close analogs of 10,
but exhibited no inhibitory effect on Pma1 at the concentrations tested. Both compounds dif-
fer from 10 by one methyl substitution, at R2 in 11 and at the nitrogen of the R1 linker in 12,
and their docking attempts gave poses that did not support any favourable hydrogen bonds. In
summary, methyl substition at R2 is not tolerated. For Pma1 inhibition and antifungal activity
the larger aromatic substitution at R1 is more favorable for antifungal activity than the shorter
substitutions and trifluoromethoxy group together with chloride, bromide, and methyl is well
tolerated at the R4 position.
Collectively, these data suggest that Pma1 inhibition is the basis for antifungal activity of the
tetrahydrocarbazole series presented herein. Of note, the location of the tetrahydrocarbazole
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binding pocket in SERCA at the cytosolic membrane interface is not directly accessible from
the extracytosolic side but requires the compound to pass through the sarcoplasmic reticulum
membrane in order to bind. Assuming the tetrahydrocarbazole binding site is located in the
corresponding pocket of Pma1, the compounds would have to pass the fungal plasma mem-
brane in order to inhibit Pma1. The exact molecular mechanism of inhibition will need to be
established in detail by dedicated kinetic studies, but the SERCA•7•TNPATP structure sug-
gests that tetrahydrocarbazole binding does not interfere with nucleotide binding by SERCA,
but instead blocks the entry of ions from the cytosolic side. Compound 7 locks M1, M2, M3
and M4 in a conformation incompatible with calcium binding and transport. The binding
pocket extends deep into the core of the protein, reaching through towards the Tg binding
groove. In fact, studies have shown how long substituents of Tg analogs can follow an intra-
membranous course and bridge the two binding pockets [33]. The observed perturbations of
M1 and M2, translating into a displacement of the A-domain furthermore induce the forma-
tion of a previously unreported tilted conformation of the cytosolic headpiece.
The tetrahydrocarbazoles tested are not specific for Pma1, and also inhibit the mammalian
SERCA and the Na+,K+-ATPase, which may partially explain their inhibitory effects on
HepG2 cell proliferation. To advance these compounds in an antifungal drug discovery pro-
gram an improved selectivity index between mammalian and fungal cells will be required.
Interestingly, the tetrahydrocarbazoles have been identified as potential drug candidates
for the treatment of Alzheimer’s disease. 1 and 2 have been identified as compounds which
can reduce the enhanced calcium release from the endoplasmic reticulum (ER) in HEK293
cells expressing the familial Alzheimer’s disease (FAD)-linked presenilin 1 mutation [34].
Since tetrahydrocarbazoles inhibit SERCA, it is likely that SERCA inhibition is the reason for
normalization of the impaired ER calcium homeostasis by these compounds. Hence, the SER-
CA•7•TNPATP crystal structure could prove useful in optimizing the tetrahydrocarbazole
series against SERCA.
Tetrahydrocarbazole derivatives with an amide group at the R1 position have been
described as potent inhibitors of human papillomaviruses [35–37]. The two most potent
tetrahydrocarbazoles with anti-viral activity [36] were synthesized (compound V1 and V2)
(Figure G in S1 File). Neither of them inhibited Pma1, nor exhibited antifungal activity against
S. cerevisiae or C. albicans (Table A in S1 File). A related chemical class of spirotetrahydro-β-
carbolines have been identified as antimalarial drug candidates targeting the P-type ATPase
PfATP4, a proposed Na+ pump regulating cytosolic Na+ [38] in the Plasmodium falciparum
parasite and have undergone a Phase II clinical trial [38–40]. The racemate of the lead com-
pound NITD609 inhibits Candida albicans Pma1 and rabbit SERCA in the low micromolar
range but is less potent on the pig Na+,K+-ATPase (Figure H in S1 File and Table B in S1 File).
However, the racemate does not have antifungal activity against C. albicans, C. krusei, or C.
parapsilosis at concentrations <75 μM. This highlights the importance of the substituent on
the tetrahydrocarbazole core for P-type ATPase selectivity and antifungal activity. Interest-
ingly, NITD609 (KAE609) has been suggested to bind to the same hydrophobic cavity in Pma1
[41] as the tetrahydrocarbazoles presented here.
This study laid the structural groundwork for the rational design of selective compounds
targeting the fungal H+-ATPase. Future work will undertake modifications to the tetrahydro-
carbazoles to increase selectivity for Pma1 over mammalian ATPases, to modulate the physico-
chemical properties to give a favorable in vivo pharmacokinetic profile, and eventually
demonstrate efficacy in an animal model of fungal infection.
In conclusion, the combined functional and structural insight gained through in vitro and
cell-based inhibition assays, crystallographic data and computational models has allowed us to
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identify a novel class of Pma1 inhibitors with broad-spectrum antifungal activity for future
optimization towards a drug candidate.
Materials and methods
Compounds 4–12, V1, V2 and racemic of NITD609 were synthesized at Aurigene Discovery
Technologies Ltd, India. Fluconazole (FLC) was purchased from Saveen & Werner AB (Swe-
den). Voriconazole (VRC) and amphotericin B (AMB) were purchased from Sigma-Aldrich
(Saint Louis, MO).
Compound library screening
The compound libraries were purchased from Enamine Ltd, Ukraine and Chembridge Corp,
USA. Library screening was performed in 96 well plates format and each compound was
screened in the ATP hydrolysis assay at a final concentration of 20 μM. DMSO was used to
determine the maximal ATPase activity and a blank with ATP in absence of Pma1 protein was
used to determine the level of spontaneous ATP hydrolysis and used to determine background
level. The percentage of compound inhibition was evaluated by subtracting the blank from
each data point and normalizing to maximal ATP hydrolysis activity. Compounds that exhib-
ited>30% Pma1 inhibition at 20 μM concentration were selected for further evaluation. Two-
fold dilution plates of the compounds were used to determine Pma1 IC50 and evaluated for
fungal growth inhibition against Saccharomyces cerevisiae (baker’s yeast) and Candida albicans
(ATCC 90028) in a concentration range of 100 μM to 1.5 μM. Pma1 inhibitory hit compounds
(IC50 <20 μM) with antifungal activity on both S. cerevisiae and C. albicans (MIC <100 μM)
were re-purchased and re-evaluated to confirm the potency and identity of the compound.
Preparation of fungal membrane fractions
Plasma membranes containing Pma1 were isolated from Saccharomyces cerevisiae RS72 cells
containing the full-length cDNA of the S. cerevisiae plasma membrane H+-ATPase isoform
PMA1 under control of the PMA1 promoter as described [42].
Candida albicans microsomes were prepared from 100 mL overnight culture in YPD (10
g/L yeast extract (BD, Sparks, MD), 20 g/L Bacto peptone (BD, Sparks, MD), 20 g/L D-(+)-glu-
cose), transferred to 1 L YPD and grown at RT, 150 rpm, for 7 h. Cells were harvested and
washed in deionized water followed by centrifugation at 3360 x g. The cells were glucose-acti-
vated by the addition of 10% (w/v) D-(+)-glucose for 10 minutes while shaking. This suspen-
sion was then centrifuged at 3,360 x g for 3 minutes and 60–80 g of cells (wet weight) were
resuspended in homogenization buffer (50 g/L glucose, 28.3% (v/v) glycerol, 100 mM Tris-
HCl pH 7.25, 10 mM EDTA pH 8.0, 50 mM KCl, 1 mM DTT, 200 μM PMSF, 2 μg/ml Pepsta-
tin A), and disrupted with 165 g glassbeads (500 μm diameter) in a BeadBeater (Biospec Prod-
uct, Bartlesville, OK). The disrupted cells were centrifuged at 4˚C for 5 and 15 minutes at 1,400
x g and 12,000 x g, respectively. The supernatant was collected and centrifuged at 251,000 x g
for 1 h, and the membrane fraction was collected and homogenized in GTEK20 buffer (20%
(v/v) glycerol, 10 mM Tris-HCl pH 7.25, 25 mM KCl, 0.5 mM EDTA pH 8.0, 1 mM DTT, 0.2
mM PMSF, 2 μg/mL Pepstatin A). Further plasma membrane purification with a sucrose gra-
dient did not improve purity, hence C. albicans microsome preparations were used in the ATP
hydrolysis assay.
All membrane batches were validated by determining ATPase activity, pH optimum and
orthovanadate sensitivity. Sarco/endoplasmatic reticulum (SR) Ca2+ ATPase was provided in
SR membranes purified by extraction with a low concentration of deoxycholate (DOC) and
was kindly provided by Claus E. Olesen and Jesper V. Møller, Aarhus University and prepared
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as described in [43]. The pig kidney Na+,K+-ATPase purification included a mild SDS treat-
ment of isolated microsomes followed by a washing step and was kindly provided by Natalya
Fedosova, Aarhus University and prepared as described in [44].
ATP hydrolysis inhibition
ATPase activity was determined by measuring the amount of liberated phosphate from ATP
hydrolysis. The ATPase assay was performed in 96 well plates in a final reaction volume of
60 μL. 0.1–0.2 μg/well of DOC extracted SERCA membrane or the Na+,K+-ATPase was used,
while 1–2.5 μg/well was used of the Pma1 membrane preparation. Reactions, including protein
membrane preparation and various concentrations of exogenously added compounds, were
conducted in the following buffers; Pma1 buffer: 17.5 mM MOPS-NaOH pH 7, 7 mM MgSO4,
44 mM KNO3 (vacuolar ATPase inhibitor), 22 mM NaN3 (mitochondrial ATPase inhibitor),
0.22 mM Na2MoO4 (acid phosphatase inhibitor); SERCA buffer: 9 mM MOPS-NaOH pH 7,
2.7 mM MgCl2, 0.1 mM CaCl2 and 72 mM KCl. Na
+,K+-ATPase buffer: 30 mM MOPS-NaOH
pH 7, 40 mM NaCl, 4 mM MgCl2 and 20 mM KCl. Reactions were initiated by the addition of
Na-ATP to a final concentration of 2.5 mM (Pma1 and Na+,K+-ATPase) or 5 mM (SERCA),
followed by 30 minutes incubation at 30˚C. The amount of liberated phosphate was deter-
mined colorimetrically after addition of STOP solution (mixture of L-ascorbic acid, ammo-
nium heptamolybdate tetrahydrate, and HCl to give final concentrations of 65 mM, 2.2 mM,
and 189 mM, respectively) with 5 minutes incubation at room temperature (RT) followed by
addition of arsenite solution (mixture of NaAsO2, sodium citrate dihydrate, and acetic acid to
give final concentrations of 3.1 mM, 28 mM, and 141 mM, respectively). Absorption was mea-
sured at 860 nm after additional 30 minutes incubation at RT.
Fungal growth inhibition
Fungal isolates were purchased from American Type Culture Collection, except for C. glabrata
strain Cg003, which was kindly provided by Julius Subik, Comenius University in Bratislava,
Slovak Republic. Cg003 is a clinical isolate, characterized to be resistant to fluconazole and itra-
conazole due to overexpression of the multidrug resistance efflux pumps Cdr1p and Cdr2p
[13]. Saccharomyces cerevisiae (ATCC 9763), Candida albicans (ATCC 90028), Candida albi-
cans (SC5314), Candida glabrata (ATCC 90030), Candida glabrata (Cg003) and Candida krusei
(ATCC 6258) were grown in Sabouraud broth (40 g/L D-glucose, 10 g/L peptone, pH 5.6) or
YPD (10 g/L yeast extract, 20 g/L Bacto-peptone, 20 g/L glucose) medium to mid log phase, ali-
quoted into 20% (v/v) glycerol and cryopreserved as stocks at -80˚C. For each growth assay,
cells from these stocks were diluted in sterile water to OD600 = 0.025, which corresponds to a
final starting inoculum of 0.5–2.5 x 105 CFU/mL. Growth assays were carried out by pipetting
3 μL compound dissolved in DMSO, 100 μL cell suspension and 97 μL 2 x RPMI media (20.8
g/L RPMI-1640 (Sigma-Aldrich catalog number R6504) 330 mM MOPS, 36 g/L glucose) into
a microtiter plate and incubating for 24 h at 34˚C, followed by OD measurement at 490 nm.
The minimum inhibitory concentration (MIC) was defined as 50% growth inhibition of the
microorganism as this measurement best represented the antifungal activity of the com-
pounds. Standard errors were typically below 5%.
Time-kill assay
C. albicans (SC5314) cells (1 x 105 CFU/mL) were incubated in 10 mL RPMI-1640 media at
30˚C with gentle agitation (150 rpm) in the presence of amphotericin B (0.5 μM), voriconazole
(2.8 μM) or tetrahydrocarbazole compound (20 μM). At the indicated time points (0, 3, 6, and
24 h), a 100 μL aliquot was removed, serially diluted (10 fold) in saline (0.9% NaCl), and 30 μL
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aliquots were spread on YPD agar. CFU were counted after incubation at 30˚C for 48 h [45].
C. albicans cells treated with DMSO (1%, v/v) served as a control. 50 CFU/mL was selected as
the lower limit of quantitation.
Post-antifungal effect determination
The post-antifungal effect (PAFE) of antifungal drugs on C. albicans was determined as
described by others [46], with modifications. Briefly, 2 × 106 CFU/mL C. albicans cells were
incubated in 1 mL RPMI-1640 media for 1 h at 30˚C with gentle agitation in the presence of
amphotericin B (0.54 μM), voriconazole (2.8 μM) or tetrahydrocarbazole compound (20 μM).
Cells were subsequently washed in RPMI media 3 times by centrifugation (3 minutes, 5,000 x
g) and finally re-suspended in 1 mL fresh RPMI medium and incubated at 30˚C for 24 h. At
various time intervals, a 100 μL aliquot was removed, serially diluted (10-fold) in saline (0.9%
NaCl), and 30 μL aliquots were spread on YPD agar. The agar plates were incubated at 30˚C
for 48 h and the number of CFU/mL of culture was determined. C. albicans cells treated with
DMSO (1%, v/v) served as a control. The number of CFU/mL obtained at specified time inter-
vals was plotted against time (h) following compound removal. An increase in the CFU/mL of
culture signifies growth and multiplication of yeast cells. The duration required for the anti-
fungal drug-treated cells to recover from the inhibitory effect of the drug as indicated by an
increase in CFU/mL of culture is defined as the PAFE.
Membrane potential and integrity study
S. cerevisiae cells were grown to mid-log phase, pelleted at 2,000 x g for 2 minutes and washed
twice in buffer A (100 mM MOPS and 1 mM KCl adjusted with Trizma base to pH 7.0). Cells
were then resuspended in buffer A to an OD600 of 0.2. For each well 50 μL of buffer A with
3.3 μg/mL propidium iodide (PI) (Thermo Fisher Scientific, catalog number P1304MP) and
1 μg/mL DiBAC4(3) (Sigma-Aldrich, catalog number D8189)) was mixed with 50 μL S. cerevi-
siae cell suspension and transferred to a 96 well plate containing 1 μL of inhibitor (in DMSO).
A lysis control was performed with Reagent Y100 (ChemoMetec). Five thousand cells were
measured per experiment with an exposure time of 1000 ms using a NucleoCounter NC-3000
(ChemoMetec). Dark field was used as the masking channel to select the yeast cells, and the
DiBAC4(3) (ex: 530 nm, em 675/75 nm) and PI (ex 630 nm, em 740/60 nm) channels were
used to measure the membrane potential and membrane integrity, respectively. Only cells
with a pixel size of 10–40 were included in the analysis, to avoid analysis of non-cell artifacts.
Hep G2 viability assay
In each well of a 96 well tissue culture plate (Greiner, catalog number GR-655180) 10,000
human hepatocyte HepG2 cells (Sigma-Aldrich, catalog number 85011430) were plated in
200 μL growth media (EMEM (Sigma-Aldrich, catalog number M2279), 2 mM L-Glutamine
(Biological Industries, catalog number 03-020-1B), 1% non-essential amino acids (Biosera,
catalog number XC-E1154/100), 10% fetal bovine serum (Biological Industries, catalog num-
ber BI-04-007-1A)), and incubated overnight at 37˚C and 5% CO2. The following day, fresh
growth media plus 2 μL compound in DMSO was added. The plate was incubated for a further
72 h at 37˚C and 5% CO2. The media was replaced with 100 μL freshly prepared 0.5 mg/mL
XTT sodium salt solution (Sigma-Aldrich, catalog number X4251) in RPMI-1640 (Sigma-
Aldrich, catalog number R7509) with 3.83 μg/mL phenazine methosulfate (Sigma-Aldrich, cat-
alog number P9625) and incubated 2–3 h at 37˚C and 5% CO2. The color reaction was mea-
sured on a Victor X5 plate reader (Perkin-Elmer) at OD450, and the half maximal effective
concentration (EC50) was calculated indicating the potency of tetrahydrocarbazole derivatives
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to inhibit HepG2 cell growth. Tamoxifen (Sigma-Aldrich, catalog number 85256) was used as
a positive control compound while DMSO served as a negative control.
Crystal structure determination
Rabbit sarcoplasmatic reticulum membranes containing SERCA were prepared as in [43].
SERCA membranes (4.3 mg) were resuspended and gently homogenized in 100 mM MOP-
S-Tris pH 6.8, 80 mM KCl, 3 mM MgCl2, 4 mM EGTA and 20% (v/v) glycerol. Compound 7
(0.5 mM final concentration) was added to the SERCA membranes and incubated overnight at
4˚C. The following day, the protein was solubilized at a detergent/protein (w/w) ratio of 1.5:1
with C12E8 followed by 10 minutes incubation before centrifugation (TLA-55 rotor, 50,000
rpm, 20 minutes, 4˚C). The concentration of solubilized protein was usually 10–12 mg/mL, to
which 0.5 mM TNPATP was added prior to crystallization. Co-crystallization of SERCA with
compound 7 was carried out using hanging drop equilibration at 23˚C with protein/buffer/
detergent in a 1:1:0.25 ratio. The best diffracting crystals were obtained by the addition of 0.1%
(w/v) of n-Octyl-β-D-galactopyranoside and buffer consisting of 7.5% glycerol, 21% PEG6000,
100 mM NaOAc pH 7.2, 6% MPD. The crystals were cryoprotected by a 10 second transfer to
a cryobuffer consisting of a 1:1 mixture of 25% glycerol and the crystallization buffer. Data was
collected at beam line PXIII at the Swiss Light Source (SLS) in Villigen, Switzerland. The data
were collected at 100 K and a wavelength of 0.9 Å, and processed using XDS and XSCALE
[47]. The structure was determined using individual domains of SERCA (pdb: 2AGV, all
ligands removed) and several rounds of molecular replacement using PHASER in PHENIX
with identification of the position of the cytoplasmic domains, followed by the transmembrane
helices. PHENIX was used for refinement [48], COOT for model building [49] and MOL-
PROBITY for model validation [50]. Data collection information and refinement statistics are
presented in Table C in S1 File. Several structural reports on SERCA and the Na+,K+-ATPase
were included in the model analysis [16–25,28,51]. The final model of SERCA bound to com-
pound 7 deviates significantly from 2AGV (overall rmsd 2.013 Å). 2AGV is very similar to the
structure 3AR7, which we compare with SERCA•7•TNPATP in Figure E in S1 File.
Homology modeling and molecular docking
For the generation of homology models, we used the software programs Schrodinger and the
module Prime. The sequence alignment between Candida albicans Pma1 and rabbit SERCA
(~20% sequence identity) was manually validated and modified using a structure-based align-
ment of SERCA with the plasma H+-ATPase from the plant Arabidopsis thaliana AHA2 [32]
and a sequence alignment of AHA2 with C. albicans PMA1 (~40% homology). The final opti-
mized alignment is illustrated in Figure I in S1 File. For building the homology model using
Prime, conserved regions were copied, non-conserved side chains replaced and optimized,
insertions built and deletions closed. Short loops were refined using the standard sampling
protocol, whereas the five longest loops were refined using an extended loop protocol. Molecu-
lar dockings were carried out with AutoDock/Vina as follows. The SERCA structure was pre-
pared with AutoDockTools [52] by adding hydrogen atoms and defining a cubic sampling
grid box with a side length of 48 Å, centered approximately in the center of the cytosolic
boundary of the transmembrane domain, encompassing all transmembrane helix regions
above the ion binding sites, the lower third of the P-domain and reaching up to the boundary
of the A domain. (Figure J in S1 File). The large size of the search space was chosen in order to
prevent a bias towards the experimentally determined binding site. The ligand molecules were
built and energy-minimized in MAESTRO (Maestro, Schro¨dinger, LLC, New York, NY, 2017)
and prepared for docking in AutoDockTools, making all relevant bonds rotatable. Nine
Tetrahydrocarbazoles inhibit the fungal H+-ATPase
PLOS ONE | https://doi.org/10.1371/journal.pone.0188620 January 2, 2018 16 / 21
docking poses were calculated with Vina (using default parameters) for each compound enan-
tiomer on the SERCA crystal structure, and the Pma1 and NKA models. All docking poses
depicted in Fig 6 are the top scoring poses according to the Autodock/Vina affinity score
(given in kcal/mole).
Supporting information
S1 File. Figure A: Membrane potential and integrity assay. S. cerevisiae cells incubated for
30 min with A: 1% DMSO, B-H: 10 μM 4–10, I: Lysis buffer. The 4 quadrants define cells as
DiBAC4(3) positive (+, top quadrants) or negative (-, bottom quadrants) and PI positive (+,
right quadrants) and negative (-, left quadrants). Figure B: Difference electron densities for
bound TNPATP and lipids. A) Bound TNPATP between the N- and P-domain (domain bor-
ders indicated by dashed lines). This binding mode is almost identical to previously reports
(pdb: 3AR7) (1). B) Residual electron density indicated the presence of two lipid molecules at
the luminal membrane interface. In accordance to the expected abundance in a sample derived
from SR membrane, two DOPC molecules were modeled. The green mesh is an mFo-DFc elec-
tron density map calculated before the ligands were added to the model, and contoured at
3.0 σ and 2.8 σ for TNPATP and DOPC, respectively. Figure C: Compound 7 binds in the
same pocket as BHQ and CPA in SERCA. Structural alignment of SERCA•7•TNPATP
(pdb:5NCQ, blue) with A) SERCA•BHQ (pdb:2AGV, salmon) and B) SERCA•CPA
(pdb:3FGO, cyan) (2, 3). The compound is cradled between M1, M2, M3 and M4 (behind the
viewpoint) inside the cavity marking the cytoplasmic end of the Ca2+ inlet channel of SERCA.
The view is from the inside of the cavity, for clarity. C) Chemical structures of BHQ and CPA.
Figure D: Binding pocket of 7 in the SERCA crystal structure and in the Pma1 homology
model. A) Binding pocket of 7 in SERCA. B) The binding pocket of 7 in the Pma1 homology
model is larger as compared to the one in the SERCA crystal structure, and it extends deeper
into the core of the protein towards transmembrane helix M5 (indicated with a white arrow).
Figure E: SERCA•7 •TNPATP crystal structure (pdb: 5NCQ, blue) superposed with the
crystal structure of SERCA•Tg •TNPATP crystal structure (pdb: 3AR7, orange). A) Overall
view of the two crystal structures superposed on transmembrane helices 7–10. All three cyto-
solic domains have undergone a positional shift. B) Top view on the N- and A-domains, super-
posed on the N-domain, illustrating the considerable displacement of the A domain (labeled
A in the SERCA•7•TNPATP structure), including the functionally important so-called
TGES-loop (residues 181–184, red and orange spheres). C) Displacement of transmembrane
helices M1 and M2 near the binding site of compound 7. These displacements translate into a
substantial backward movement of the A- domain and smaller displacements of the P- and N-
domains as compared to all other known SERCA structures. Figure F: Docking of THCs into
the Na+,K+-ATPase homology model. Structural overlay of compound 7 (yellow) within the
SERCA crystal structure with the docking results of compound 4–12 docked into the Na+,K+-
ATPase homology model. None of the compounds gave a docking position similar as to the
observed position of 7 in SERCA, due to a steric clash with Phe100, a residue previously dis-
cussed to be responsible for the resistance of the Na+,K+-ATPase to CPA (Laursen, Bublitz
et al, 2009)(3). Figure G: Compound V1 and V2 identified as viral inhibitors. Compound 25
and 26 in Gudmundsson et al., 2009 (4). Table A: ATP hydrolysis and fungal growth effect
of V1 and V2. Figure H: The racemic compound of NITD609. Synthesis described in Dan-
dapani et al., 2012 (5). Table B: ATP hydrolysis and fungal growth effect of the racemic of
NITD609. Table C. Data collection and refinement statistics. Figure I: Sequence alignment
of Candida albicans Pma1 and rabbit SERCA used as basis for homology modeling. Resi-
dues with polar interactions to compound 7 and their equivalents in the Pma1 homology
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model are marked with red asterisks, other residues surrounding the binding site are marked
with black asterisks. Note that Q101 in the Pma1 model is at an almost equivalent position as
SERCA D59. Figure J: Graphical representation of the grid box used as sampling space for
docking with AutoDock/Vina.
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